Literature DB >> 19728987

Liver X receptor regulates expression of MRP2 but not that of MDR1 and BCRP in the liver.

Ikumi Chisaki1, Masaki Kobayashi, Shirou Itagaki, Takeshi Hirano, Ken Iseki.   

Abstract

Liver X receptors (LXRs) belong to the nuclear hormone receptor superfamily. Multidrug resistance-associated protein 2 (MRP2), multidrug resistance 1 (MDR1) and breast cancer resistance protein (BCRP) play an important role in the efflux of a broad range of endogenous and xenobiotic compounds from hepatocytes. Since the effects of LXR activation on there transporters have been obscure, we investigated the effects of LXR agonists, TO901317 and 25-hydroxycholesterol, on MRP2, MDR1, BCRP expression in HepG2 cells and the rat liver. In an in vitro study, TO901317 increased ABCA1, an LXR target gene, and MRP2 mRNA and protein levels. On the other hand, TO901317 had little effect on MDR1 and BCRP mRNA levels. In an in vivo study, Abca1 and Mrp2 mRNA and protein levels were increased by TO901317, but TO901317 had no effect on Mdr1a and Bcrp mRNA levels in the rat liver. Moreover, TO901317-induced MRP2 mRNA expression was blocked by LXRalpha knockdown. In this study, we demonstrated that LXR activation induced expression of MRP2 but not that of MDR1 and BCRP in hepatocytes. The results suggest that agonists for LXR activate transcription of the MRP2 gene in order to promote excretion of endogenous and xenobiotic compounds from hepatocytes into bile.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19728987     DOI: 10.1016/j.bbamem.2009.08.014

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  The bladder tumor suppressor protein TERE1 (UBIAD1) modulates cell cholesterol: implications for tumor progression.

Authors:  William J Fredericks; Terry McGarvey; Huiyi Wang; Priti Lal; Raghunath Puthiyaveettil; John Tomaszewski; Jorge Sepulveda; Ed Labelle; Jayne S Weiss; Michael L Nickerson; Howard S Kruth; Wolfgang Brandt; Ludger A Wessjohann; S Bruce Malkowicz
Journal:  DNA Cell Biol       Date:  2011-07-08       Impact factor: 3.311

2.  Polymorphisms in NF-κB, PXR, LXR, PPARγ and risk of inflammatory bowel disease.

Authors:  Vibeke Andersen; Jane Christensen; Anja Ernst; Bent A Jacobsen; Anne Tjønneland; Henrik B Krarup; Ulla Vogel
Journal:  World J Gastroenterol       Date:  2011-01-14       Impact factor: 5.742

3.  ATP-binding cassette transporter A1: A promising therapy target for prostate cancer.

Authors:  Ting Xiong; Gang Xu; Xue-Long Huang; Kai-Qiang Lu; Wei-Quan Xie; Kai Yin; Jian Tu
Journal:  Mol Clin Oncol       Date:  2017-11-15

4.  Polymorphisms in NFkB, PXR, LXR and risk of colorectal cancer in a prospective study of Danes.

Authors:  Vibeke Andersen; Jane Christensen; Kim Overvad; Anne Tjønneland; Ulla Vogel
Journal:  BMC Cancer       Date:  2010-09-13       Impact factor: 4.430

5.  HDAC inhibitor-induced drug resistance involving ATP-binding cassette transporters (Review).

Authors:  Xuan Ni; Li Li; Guoyu Pan
Journal:  Oncol Lett       Date:  2014-11-19       Impact factor: 2.967

Review 6.  ABC transporters in fish species: a review.

Authors:  Marta Ferreira; Joana Costa; Maria A Reis-Henriques
Journal:  Front Physiol       Date:  2014-07-22       Impact factor: 4.566

Review 7.  The regulation of drug-metabolizing enzymes and membrane transporters by inflammation: Evidences in inflammatory diseases and age-related disorders.

Authors:  Kuo-Chen Wu; Chun-Jung Lin
Journal:  J Food Drug Anal       Date:  2018-12-04       Impact factor: 6.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.